Pharmacy Benefits Management Services Home

Although the study did not have a comparator arm or control group, the incidence of MACE, all-cause mortality, and cardiac deaths at 52 weeks was 7.3%, 3.6%, and 2.1%, respectively.5 In the second study, investigators retrospectively compared the incidence of MACE between various doses of pitavastatin, pravastatin, atorvastatin and placebo in ... ................
................